Doshi Laboratory

The hemophilias are X-linked bleeding disorders resulting from defects in coagulation factor VIII or IX. These disorders manifest as frequent bleeding episodes either spontaneously or in response to minor trauma. These patients are treated with either prophylactic infusions of factor VIII/IX concentrates, or more recently, non-factor therapeutics. The major complication of factor replacement therapy is the development of neutralizing alloantibodies, or inhibitors, in up to 30% of patients. These antibodies are most common in patients with severe factor VIII deficiency.

The Doshi Laboratory is interested in processes that drive alloantibody and anti-drug antibody responses. They investigate the reasons behind the enhanced immune response to factor VIII with the goal of leveraging this mechanism for targeted therapeutic development and interventions.

Other projects in the laboratory are focused on gene transfer for hemophilia and the immune response to adeno-associated viral vectors.